Business Description
Centessa Pharmaceuticals PLC
ISIN : US1523091007
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.51 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.82 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -128.1 | |||||
3-Year EPS without NRI Growth Rate | -118.7 | |||||
3-Year FCF Growth Rate | -123.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 14.36 | |||||
9-Day RSI | 25.3 | |||||
14-Day RSI | 33.16 | |||||
6-1 Month Momentum % | 58.47 | |||||
12-1 Month Momentum % | 127.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8 | |||||
Quick Ratio | 8 | |||||
Cash Ratio | 6.51 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -1.45 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2499.39 | |||||
Net Margin % | -2204.66 | |||||
FCF Margin % | -2342.2 | |||||
ROE % | -53.89 | |||||
ROA % | -38.18 | |||||
ROIC % | -326.22 | |||||
ROC (Joel Greenblatt) % | -1529.86 | |||||
ROCE % | -46.11 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 126.54 | |||||
PB Ratio | 3.73 | |||||
Price-to-Tangible-Book | 3.73 | |||||
EV-to-EBIT | -4.35 | |||||
EV-to-EBITDA | -4.38 | |||||
EV-to-Revenue | 105.61 | |||||
EV-to-FCF | -4.51 | |||||
Price-to-Net-Current-Asset-Value | 4.62 | |||||
Price-to-Net-Cash | 6.66 | |||||
Earnings Yield (Greenblatt) % | -22.99 | |||||
FCF Yield % | -17.94 |